Ulyanovsk Medico-biological Journal

CLINICAL MEDICINE

Download article

УДК 577.29:577.17.05:616-092.6:616-06:[616.9:578.834.1+616-006.6:616.24-006]

DOI 10.34014/2227-1848-2023-1-74-90

ENDOTHELIN-1 LEVEL IN BLOOD AND LUNG TISSUE IN POST-COVID-19 PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA

O.I. Kit, E.M. Frantsiyants, D.A. Kharagezov, E.I. Surikova, I.A. Goroshinskaya, V.A. Bandovkina, N.D. Cheryarina, A.I. Shikhlyarova, Yu.A. Pogorelova, T.G. Ayrapetova,Yu.N. Lazutin, A.G. Milakin, I.A. Leyman, O.N. Stateshnyy

National Medical Research Centre for Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

 

Long-term consequences of COVID-19 are associated with persistent endothelial dysfunction, so it is important to study both infectious and oncological processes.

The aim of the study was to examine endothelin-1 (ET-1) level in the blood and lung tissues of post-COVID-19 patients (men and women) with non-small cell lung carcinoma (NSCLC).

Materials and Methods. We examined 60 patients (59.1±3.9 years of age) with verified NSCLC, T1-3NxM0, hospitalized at the National Medical Research Center for Oncology in 2020–2021. All patients had a history of asymptomatic/mild COVID-19 (control group) or severe/moderate COVID-19 (main group). We also examined 15 healthy people (of the same age and sex) who did not suffer from COVID-19 at the time of blood sampling (donor group). The levels of endothelin-1 (ET-1-38, ET-1-21) were measured by ELISA in blood plasma of all trial subjects and in lung tissues these parameters were measured only in NSCLC patients before treatment.

Results. In NSCLC patients of the main group, ET-1-21 level in plasma was on average twice as high as that in the control group and in donors. In the tumor and the perifocal zone, ET-1-21 level was higher than that in the resection line tissue: by 1.4–2.7 times in the control group, by 1.6–7.6 times in the main group in men and women. At the same time, women of the main group had a significantly more pronounced increase in ET-1-21 level in the perifocal zone and a decrease in the tumor tissue compared to that in the control group. ET-1-38 level in the control group was 3 and 2.1 times as low as in the tumor and perifocal zone, and in the main group it was 2.8 times as high in the perifocal zone in women as that in the resection line tissue. Gender differences in ET-1 level in both groups of patients were revealed.

Conclusion. In NSCLC post-COVID-19 patients, changes in the endothelin-1 level were found, which could be caused not only by long-term endothelium dysfunction, but which also could modify NSCLC development.

Key words: lung cancer, COVID-19, coronavirus infection, severity, gender differences, blood, tumor, tumor perifocal zone, endothelin-1.

 

Conflict of interest. The authors declare no conflict of interest.

Author contributions
Research concept and design: Kit O.I., Frantsiyants E.M., Kharagezov D.A.
Experimental design: Kharagezov D.A., Lazutin Yu.N.
Participation in the research study, data processing: Ayrapetova T.G., Leyman I.A., Milakin A.G., Stateshnyy O.N.
ELISA analysis, statistical data processing: Pogorelova Yu.A., Cheryarina N.D.
Data analysis and interpretation: Goroshinskaya I.A., Shikhlyarova A.I., Bandovkina V.A., Surikova E.I.
Text writing and editing: Surikova E.I., Lazutin Yu.N.

 

References

  1. Kit O.I., Gevorkyan Yu.A., Soldatkina N.V., Gevorkyan E.Yu. Osobennosti lecheniya patsientov s onkologicheskimi zabolevaniyami i provedenie klinicheskikh issledovaniy v oblasti onkologii v uslo-

    viyakh pandemii COVID-19: opyt zarubezhnykh stran [Cencer treatment and research in the context of COVID-19 pandemic: The experience of foreign countries]. Vestnik Rossiyskoy akademii meditsinskikh nauk. 2020; 75 (4): 278–282. DOI: 10.15690/vramn1384 (in Russian).

  2. Bian D.J.H., Sabri S., Abdulkarim B.S. Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic. Cancers (Basel). 2022; 14 (15): 3598. DOI: 10.3390/cancers14153598.

  3. Rolfo C., Meshulami N., Russo A., Krammer F., García-Sastre A., Mack P.C., Gomez J.E., Bhardwaj N., Benyounes A., Sirera R., Moore A., Rohs N., Henschke C.I., Yankelevitz D., King J., Shyr Y., Bunn P.A.Jr., Minna J.D., Hirsch F.R. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. J Thorac Oncol. 2022; 17 (2): 214–227. DOI: 10.1016/j.jtho.2021.11.001.

  4. Gulyaev P.V., Resnyanskaya S.V., Ostrovskaya I.V. Vyyavlenie postkovidnogo sindroma u patsientov, perenesshikh novuyu koronavirusnuyu infektsiyu [Detection of post-coronavirus syndrome in patients who have had a new coronavirus infection]. Sovremennye problemy zdravookhraneniya i meditsinskoy statistiki. 2022; (S2): 107–128. DOI: 10.24412/2312-2935-2022-2-107-128 (in Russian).

  5. Pogosova N.V., Paleev F.N., Ausheva A.K., Kuchiev D.T., Gaman S.A., Veselova T.N., Bel'kind M.B., Sokolova O.Yu., Zhetisheva R.A., Ternovoy S.K., Boytsov S.A. Posledstviya COVID-19 na otdalennom etape posle gospitalizatsii [Sequelae of COVID-19 at long-term follow-up after hospitalization]. Ratsional'naya farmakoterapiya v kardiologii. 2022; 18 (2): 118–126. DOI: 10.20996/1819-6446-2022-04-03 (in Russian).

  6. Charfeddine S., Ibn Hadj Amor H., Jdidi J., Torjmen S., Kraiem S., Hammami R., Bahloul A., Kallel N., Moussa N., Touil I., Ghrab A., Elghoul J., Meddeb Z., Thabet Y., Kammoun S., Bouslama K., Milouchi S., Abdessalem S., Abid L. Long COVID-19 Syndrome: Is It Related to Microcirculation and Endothelial Dysfunction? Insights From TUN-EndCOV Study. Front Cardiovasc Med. 2021; 8: 745758. DOI: 10.3389/fcvm.2021.745758.

  7. Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S., Mehra M.R., Schuepbach R.A., Ruschitzka F., Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395 (10234): 1417–1418. DOI: 10.1016/S0140-6736(20)30937-5.

  8. Carpenter T.C., Schomberg S., Stenmark K.R. Endothelin-mediated increases in lung VEGF content promote vascular leak in young rats exposed to viral infection and hypoxia. Am J Physiol Lung Cell Mol Physiol. 2005; 289 (6): L1075– L1082. DOI: 10.1152/ajplung.00251.2005.

  9. Barton M., Yanagisawa M. Endothelin: 30 Years From Discovery to Therapy. Hypertension. 2019; 74 (6): 1232–1265. DOI: 10.1161/HYPERTENSIONAHA.119.12105.

  10. Masaki T. Historical review: Endothelin. Trends Pharmacol Sci. 2004; 25 (4): 219–224. DOI: 10.1016/ j.tips.2004.02.008.

  11. Krishnarao K., Bruno K.A., Di Florio D.N., Edenfield B.H., Whelan E.R., Macomb L.P., McGuire M.M., Hill A.R., Ray J.C., Cornell L.F., Tan W., Geiger X.J., Salomon G.R., Douglas, E.J., Fairweather D., Yamani M.H. Upregulation of Endothelin-1 May Predict Chemotherapy-Induced Cardiotoxicity in Women with Breast Cancer. Journal of clinical medicine. 2022; 11 (12): 3547. DOI: https://doi.org/ 10.3390/jcm11123547.

  12. Tamkus D., Sikorskii A., Gallo K.A., Wiese D.A., Leece C., Madhukar B.V., Chivu S.C., Chitneni S., Dimitrov N.V. Endothelin-1 enriched tumor phenotype predicts breast cancer recurrence. ISRN Oncol. 2013; 2013: 385398. DOI: 10.1155/2013/385398 

  13. Gupta S., Prajapati A., Gulati M., Gautam S.K., Kumar S., Dalal V., Talmon G.A., Rachagani S., Jain M. Irreversible and sustained upregulation of endothelin axis during oncogene-associated pancreatic inflammation and cancer. Neoplasia. 2020; 22 (2): 98–110. DOI: 10.1016/j.neo.2019.11.001.

  14. Tocci P., Blandino G., Bagnato A. YAP and endothelin-1 signaling: an emerging alliance in cancer. J Exp Clin Cancer Res. 2021; 40: 27. DOI: https://doi.org/10.1186/s13046-021-01827-8

  15. Ahn H.M., Kim D.G., Kim Y.J. Blockade of endothelin receptor A enhances the therapeutic efficacy of gemcitabine in pancreatic cancer cells. Biochem Biophys Res Commun. 2020; 527 (2): 568–573. DOI: 10.1016/j.bbrc.2020.04.118.

  16. Bermejo-Martin J.F., Almansa R., Torres A., González-Rivera M., Kelvin D.J. COVID-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction. Cardiovasc Res. 2020; 116 (10): e132–e133. DOI: 10.1093/cvr/cvaa140.

  17. Abraham G.R., Kuc R.E., Althage M., Greasley P.J., Ambery P., Maguire J.J., Wilkinson I.B., Xu S.W., Ilyas I., Weng J.P. Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol Sin. 2022: 1–15. DOI: 10.1038/s41401-022-00998-0.

  18. Hoole S.P., Cheriyan J., Davenport A.P. Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19. J Mol Cell Cardiol. 2022; 167: 92–96. DOI: 10.1016/j.yjmcc.2022.03.007.

  19. Kadiyska T., Tourtourikov I., Dabchev K., Cherneva R., Stoynev N., Hadjiolova R., Mitev V., Spandidos D.A., Adamaki M., Zoumpourlis V. Role of endothelial dysfunction in the severity of COVID‑19 infection (Review). Mol Med Rep. 2022; 26 (5): 351. DOI: 10.3892/mmr.2022.12867.

  20. Santoro L., Falsetti L., Zaccone V., Nesci A., Tosato M., Giupponi B., Savastano M.C., Moroncini G., Gasbarrini A., Landi F., Santoliquido A. On Behalf of Gemelli Against Covid-Post-Acute Care Study Group. Impaired Endothelial Function in Convalescent Phase of COVID-19: A 3 Month Follow Up Observational Prospective Study. J Clin Med. 2022; 11 (7): 1774. DOI: 10.3390/jcm11071774.

  21. Oikonomou E., Souvaliotis N., Lampsas S., Siasos G., Poulakou G., Theofilis P., Papaioannou T.G., Haidich A.B., Tsaousi G., Ntousopoulos V., Sakka V., Charalambous G., Rapti V., Raftopoulou S., Syrigos K., Tsioufis C., Tousoulis D., Vavuranakis M. Endothelial dysfunction in acute and long standing COVID-19: A prospective cohort study. Vascul Pharmacol. 2022; 144: 106975. DOI: 10.1016/j.vph.2022.106975.

  22. Haffke M., Freitag H., Rudolf G., Seifert M., Doehner W., Scherbakov N., Hanitsch L., Wittke K., Bauer S., Konietschke F., Paul F., Bellmann-Strobl J., Kedor C., Scheibenbogen C., Sotzny F. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). J Transl Med. 2022; 20: 138. DOI: https://doi.org/10.1186/s12967-022-03346-2

  23. Kedor C., Freitag H., Meyer-Arndt L., Wittke K., Hanitsch L.G., Zoller T., Steinbeis F., Haffke M., Rudolf G., Heidecker B., Bobbert T., Spranger J., Volk H.D., Skurk C., Konietschke F., Paul F., Behrends U., Bellmann-Strobl J., Scheibenbogen C. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. Nat Commun. 2022; 13 (1): 6009. DOI: 10.1038/s41467-022-33784-x.

  24. Petrishchev N.N., Khalepo O.V., Vavilenkova Yu.A., Vlasov T.D. COVID-19 i sosudistye narusheniya (obzor literatury) [COVID-19 and vascular disorders (literature review)]. Regionarnoe krovoobrashchenie i mikrotsirkulyatsiya. 2020; 19 (3): 90–98. DOI: 10.24884/1682-6655-2020-19-3-90-98 (in Russian).

  25. Zolotnitskaya V.P., Amosov V.I., Titova O.N., Agafonov A.O., Amosova O.V. Narusheniya mikrotsirkulyatsii v legkikh po dannym perfuzionnoy OFEKT u patsientov v postkovidnom periode [Microcirculation disorders in the lungs according to perfusion SPECT-imaging in post-COVID patients]. Rossiyskiy elektronnyy zhurnal luchevoy diagnostiki. 2021; 11 (2): 8–18. DOI: 10.21569/2222-7415-2021-11-1-125-136 (in Russian).

  26. Sommer N., Schmeck B. Pulmonale Manifestationen bei Long-COVID [Pulmonary manifestations in long COVID]. Inn Med (Heidelb). 2022; 63 (8): 819–829. DOI: 10.1007/s00108-022-01371-3.

  27. Arun C., DeCatris M., Hemingway D.M., London N.J., O'Byrne K.J. Endothelin-1 is a novel prognostic factor in non-small cell lung cancer. Int J Biol Markers. 2004; 19 (4): 262–167. DOI: 10.1177/ 172460080401900402.

  28. Boldrini L., Gisfredi S., Ursino S., Faviana P., Lucchi M., Melfi F., Mussi A., Basolo F., Fontanini G. Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. Eur J Cancer. 2005; 41 (18): 2828–35. DOI: 10.1016/j.ejca.2005.08.030.

  29. Jiang Y., Liu Y., Shi Z., Wang B., Shang L., Xu X., Zhang S., Wang M. Expression and clinical relevance of uPA and ET-1 in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2011; 14 (1): 49–53. DOI: 10.3779/j.issn.1009-3419.2011.01.10.

  30. Rosanò L., Spinella F., Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2013; 13 (9): 637–651. DOI: 10.1038/nrc3546.

  31. Davenport A.P., Hyndman K.A., Dhaun N., Southan C., Kohan D.E., Pollock J.S., Pollock D.M., Webb D.J., Maguire J.J. Endothelin. Pharmacol Rev. 2016; 68 (2): 357–418. DOI: 10.1124/pr.115.011833.

  32. Rosanò L., Bagnato A. Endothelin therapeutics in cancer: Where are we? Am J Physiol Regul Integr Comp Physiol. 2016; 310 (6): R469–R475. DOI: 10.1152/ajpregu.00532.2015.

  33. Zhang Z., Chen L., Xu W., Sigdel K., Jiang X. Effects of silencing endothelin‑1 on invasion and vascular formation in lung cancer. Oncology Letters. 2017; 13: 4390–4396. DOI: https://doi.org/10.3892/ol.2017.6027

  34. Kharagezov D.A., Lazutin Yu.N., Mirzoyan E.A., Milakin A.G., Stateshnyy O.N., Leyman I.A., Chubaryan A.V., Iozefi K.D. Molekulyarnye misheni nemelkokletochnogo raka legkogo (NMRL) vne «glavnoy troyki» [Molecular targets of non-small cell lung carcinoma (NSCLC) outside the “top three”]. Yuzhno-Rossiyskiy onkologicheskiy zhurnal. 2021; 2 (4): 38–47. DOI: https://doi.org/10.37748/2686-9039-2021-2-4-5 (in Russian).

  35. Moody T.W., Ramos-Alvarez I., Moreno P., Mantey S.A., Ridnour L., Wink D., Jensen R.T. Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells. Peptides. 2017; 90: 90–99. DOI: 10.1016/j.peptides.2017.01.012.

  36. Pulido I., Ollosi S., Aparisi S., Becker J.H., Aliena-Valero A., Benet M., Rodríguez M.L., López A., Tamayo-Torres E., Chuliá-Peris L., García-Cañaveras J.C., Soucheray M., Dalheim A.V., Salom J.B., Qiu W., Kaja S., Fernández-Coronado J.A., Alandes S., Alcácer J., Al-Shahrour F., Borgia J.A., Juan O., Nishimura M.I., Lahoz A., Carretero J., Shimamura T. Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma. Cancer Res. 2020; 80 (19): 4224–4232. DOI: 10.1158/0008-5472.CAN-20-0141.

  37. Spinella F., Caprara V., Cianfrocca R., Rosanò L., Di Castro V., Garrafa E., Natali P.G., Bagnato A. The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. Carcinogenesis. 2014; 35 (4): 840–848. DOI: 10.1093/carcin/bgu018.

  38. Weigert A., Zheng X., Nenzel A., Turkowski K., Günther S., Strack E., Sirait-Fischer E., Elwakeel E., Kur I.M., Nikam V.S., Valasarajan C., Winter H., Wissgott A., Voswinkel R., Grimminger F., Brüne B., Seeger W., Pullamsetti S.S., Savai R. Fibrocytes boost tumor-supportive phenotypic switches in the lung cancer niche via the endothelin system. Nat Commun. 2022; 13 (1): 6078. DOI: 10.1038/s41467-022-33458-8.

  39. Tostes R.C., Fortes Z.B., Callera G.E., Montezano A.C., Touyz R.M., Webb R.C., Carvalho M.H. Endothelin, sex and hypertension. Clin Sci (Lond). 2008; 114 (2): 85–97. DOI: 10.1042/CS20070169.

  40. Miller V.M., Mulvagh S.L. Sex steroids and endothelial function: translating basic science to clinical practice. Trends Pharmacol Sci. 2007; 28 (6): 263–270. DOI: 10.1016/j.tips.2007.04.004.

  41. Polderman K.H., Stehouwer C.D., van Kamp G.J., Schalkwijk C.G., Gooren L.J. Modulation of plasma endothelin levels by the menstrual cycle. Metabolism. 2000; 49 (5): 648–650. DOI: 10.1016/s0026-0495(00)80042-6.

  42. Wilbert-Lampen U., Seliger C., Trapp A., Straube F., Plasse A. Female sex hormones decrease constitutive endothelin-1 release via endothelial sigma-1/cocaine receptors: an action independent of the steroid hormone receptors. Endothelium. 2005; 12 (4): 185–191. DOI: 10.1080/10623320500227275.

  43. Chkhaidze I.Z., Lioznov D.A., Petrishchev N.N., Niauri D.A. Sistemnyy endoteliit pri novoy koronavirusnoy infektsii COVID-19: gendernye i perinatal'nye riski [Endothelial dysfunction as the typical pathological state. Regional blood circulation and microcirculation]. Regionarnoe krovoobrashchenie i mikrotsirkulyatsiya. 2021; 20 (4): 4–13. DOI: 10.24884/1682-6655-2021-20-4-4-13 (in Russian).

  44. Ambrosino P., Calcaterra I., Molino A., Moretta P., Lupoli R., Spedicato G.A., Papa A., Motta A., Maniscalco M., Di Minno M.N.D. Persistent Endothelial Dysfunction in Post-Acute COVID-19 Syndrome: A Case-Control Study. Biomedicines. 2021; 9 (8): 957. DOI: 10.3390/biomedicines9080957.

 Received November 21, 2022; accepted December 03, 2022.

 

Information about the authors

Kit Oleg Ivanovich, Doctor of Sciences (Medicine), Professor, Academician of the Russian Academy of Medical Sciences, Director General, National Medical Research Center for Oncology, Ministry of Health of the Russian Federation. 344037, Russia, Rostov-on-Don, 14-ya liniya, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0003-3061-6108

Frantsiyants Elena Mikhaylovna, Doctor of Sciences (Biology), Professor, Deputy General Director, National Medical Research Center for Oncology, Ministry of Health of the Russian Federation. 344037, Russia, Rostov-on-Don, 14-ya liniya, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: http://orcid.org/0000-0003-3618-6890

Kharagezov Dmitriy Akimovich, Candidate of Sciences (Medicine), Head of the Department of Thoracic Surgery, National Medical Research Center for Oncology, Ministry of Health of the Russian Federation. 344037, Russia, Rostov-on-Don, 14-ya liniya, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: http://orcid.org/0000-0003-0640-2994

Surikova Ekaterina Igorevna, Candidate of Sciences (Biology), Senior Researcher, Laboratory for the Study of Malignant Tumor Pathogenesis, National Medical Research Center for Oncology, Ministry of Health of the Russian Federation. 344037, Russia, Rostov-on-Don, 14-ya liniya, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0002-4318-7587

Goroshinskaya Irina Aleksandrovna, Doctor of Sciences (Biology), Professor, Senior Researcher, Laboratory for the Study of Malignant Tumor Pathogenesis, National Medical Research Center for Oncology, Ministry of Health of the Russian Federation. 344037, Russia, Rostov-on-Don, 14-ya liniya, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0001-6265-8500

Bandovkina Valeriya Akhtyamovna, Doctor of Sciences (Biology), Senior Researcher, Laboratory for the Study of Malignant Tumor Pathogenesis, National Medical Research Center for Oncology, Ministry of Health of the Russian Federation. 344037, Russia, Rostov-on-Don, 14-ya liniya, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: http://orcid.org/0000-0002-2302-8271

Cheryarina Natal'ya Dmitrievna, Laboratory Assistant, Laboratory for the Study of Malignant Tumor Pathogenesis, National Medical Research Center for Oncology, Ministry of Health of the Russian Federation. 344037, Russia, Rostov-on-Don, 14-ya liniya, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: http://orcid.org/0000-0002-3711-8155

Shikhlyarova Alla Ivanovna, Doctor of Sciences (Biology), Professor, Senior Researcher, Laboratory for the Study of Malignant Tumor Pathogenesis, National Medical Research Center for Oncology, Ministry of Health of the Russian Federation. 344037, Russia, Rostov-on-Don, 14-ya liniya, 63; e-mail This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0003-2943-7655

Pogorelova Yuliya Aleksandrovna, Candidate of Sciences (Biology), Senior Researcher, Laboratory for the Study of Malignant Tumor Pathogenesis, National Medical Research Center for Oncology, Ministry of Health of the Russian Federation. 344037, Russia, Rostov-on-Don, 14-ya liniya, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: http://orcid.org/0000-0002-2674-9832

Ayrapetova Tamara Georgievna, Candidate of Sciences (Medicine), Surgeon, Department of Thoracic Surgery, National Medical Research Center for Oncology, Ministry of Health of the Russian Federation. 344037, Russia, Rostov-on-Don, 14-ya liniya, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/ 0000-0003-4188-3746

Lazutin Yuriy Nikolaevich, Candidate of Sciences (Medicine), Associate Professor, Leading Researcher, Department of Thoracic Surgery, National Medical Research Center for Oncology, Ministry of Health of the Russian Federation. 344037, Russia, Rostov-on-Don, 14-ya liniya, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.,
ORCID ID: http://orcid.org/0000-0002-6655-7632

Milakin Anton Grigor'evich, Oncologist, Department of Thoracic Surgery, National Medical Research Center for Oncology, Ministry of Health of the Russian Federation. 344037, Russia, Rostov-on-Don, 14-ya liniya, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: http://orcid.org/0000-0002-2589-7606

Leyman Igor' Aleksandrovich, Candidate of Sciences (Medicine), Oncologist, Department of Thoracic Surgery, National Medical Research Center for Oncology, Ministry of Health of the Russian Federation. 344037, Russia, Rostov-on-Don, 14-ya liniya, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: http://orcid.org/0000-0003-2572-1624

Stateshnyy Oleg Nikolaevich, Oncologist, Department of Thoracic Surgery, National Medical Research Center for Oncology, Ministry of Health of the Russian Federation. 344037, Russia, Rostov-on-Don, 14-ya liniya, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: http://orcid.org/0000-0003-4513-7548

 

For citation

Kit O.I., Frantsiyants E.M., Kharagezov D.A., Surikova E.I., Goroshinskaya I.A., Bandovkina V.A., Cheryarina N.D., Shikhlyarova A.I., Pogorelova Yu.A., Ayrapetova T.G., Lazutin Yu.N., Milakin A.G., Leyman I.A., Stateshnyy O.N. Uroven' endotelina-1 v krovi i tkani legkogo u bol'nykh nemelkokletochnym rakom legkogo, perenesshikh COVID-19 razlichnoy stepeni tyazhesti [Endothelin-1 level in blood and lung tissue in post-COVID-19 patients with non-small cell lung cancer]. Ul'yanovskiy mediko-biologicheskiy zhurnal. 2023; 1: 74–90. DOI: 10.34014/2227-1848-2023-1-74-90 (in Russian).

 

 

Скачать статью

УДК 577.29:577.17.05:616-092.6:616-06:[616.9:578.834.1+616-006.6:616.24-006]

DOI 10.34014/2227-1848-2023-1-74-90

УРОВЕНЬ ЭНДОТЕЛИНА-1 В КРОВИ И ТКАНИ ЛЕГКОГО У БОЛЬНЫХ НЕМЕЛКОКЛЕТОЧНЫМ РАКОМ ЛЕГКОГО, ПЕРЕНЕСШИХ COVID-19 РАЗЛИЧНОЙ СТЕПЕНИ ТЯЖЕСТИ

О.И. Кит, Е.М. Франциянц, Д.А. Харагезов, Е.И. Сурикова, И.А. Горошинская, В.А. Бандовкина, Н.Д. Черярина, А.И. Шихлярова, Ю.А. Погорелова, Т.Г. Айрапетова, Ю.Н. Лазутин, А.Г. Милакин, И.А. Лейман, О.Н. Статешный

ФГБУ «Национальный медицинский исследовательский центр онкологии» Минздрава России, г. Ростов-на-Дону, Россия

 

Долгосрочные последствия COVID-19 связаны со стойкой эндотелиальной дисфункцией, поэтому актуально исследование взаимного влияния инфекционного и онкологического процессов.

Цель исследования – изучение содержания эндотелина-1 (ЕТ-1) в крови и тканях легкого больных (мужчин и женщин) немелкоклеточным раком легкого (НМРЛ), перенесших новую коронавирусную инфекцию различной степени тяжести.

Материалы и методы. Обследовано 60 больных (59,1±3,9 года) верифицированным НМРЛ, T1-3NxM0, госпитализированных в НМИЦ онкологии в 2020–2021 гг., перенесших COVID-19 бессимптомно / в легкой форме (контрольная группа) или в тяжелой / среднетяжелой форме (основная группа). Также обследовано 15 здоровых людей (сопоставимых по возрасту, полу), не болевших COVID-19 на момент забора крови (группа доноров). Изучили содержание обеих форм эндотелина-1 (ЕТ-1-38, ЕТ-1-21) методом ИФА в плазме крови (у всех), в тканях легкого у больных НМРЛ до лечения.

Результаты. У больных НМРЛ основной группы уровень ЕТ-1-21 в плазме был выше в среднем в 2 раза, чем в контрольной группе и у доноров. В опухоли и перифокальной зоне уровень ЕТ-1-21 был выше, чем в ткани линии резекции: в 1,4–2,7 раза в контрольной, в 1,6–7,6 раза в основной группах у мужчин и женщин. При этом у женщин основной группы наблюдалось значительно более выраженное увеличение уровня ЕТ-1-21 в перифокальной зоне и снижение в опухоли по сравнению с его уровнем в контрольной группе. ЕТ-1-38 в контрольной группе был ниже в 3 и 2,1 раза в опухоли и перифокальной зоне, а в основной группе – выше в 2,8 раза только у женщин в перифокальной зоне по сравнению с тканью линии резекции. Выявлены половые различия уровня ЕТ-1 в обеих группах больных.

Выводы. У больных НМРЛ, имевших в анамнезе тяжелое течение COVID-19, обнаружены изменения уровня эндотелина-1, возможно, не только обусловленные длительными нарушениями функционирования эндотелия, но и способные модифицировать течение НМРЛ.

Ключевые слова: рак легкого, COVID-19, коронавирусная инфекция, тяжесть течения, половые различия, кровь, опухоль, перифокальная зона опухоли, эндотелин-1.

 

Конфликт интересов. Авторы заявляют об отсутствии конфликта интересов.

Вклад авторов
Концепция и дизайн исследования: Кит О.И., Франциянц Е.М., Харагезов Д.А.
Планирование эксперимента: Харагезов Д.А., Лазутин Ю.Н.
Участие в исследовании, обработка клинического материала: Айрапетова Т.Г., Лейман И.А., Милакин А.Г., Статешный О.Н.
Проведение ИФА-анализа, статистическая обработка данных: Погорелова Ю.А., Черярина Н.Д.
Анализ и интерпретация данных: Горошинская И.А., Шихлярова А.И., Бандовкина В.А., Сурикова Е.И.
Написание и редактирование текста: Сурикова Е.И., Лазутин Ю.Н.

 

Литература

  1. Кит О.И., Геворкян Ю.А., Солдаткина Н.В., Геворкян Э.Ю. Особенности лечения пациентов с онкологическими заболеваниями и проведение клинических исследований в области онкологии в условиях пандемии COVID-19: опыт зарубежных стран. Вестник Российской академии медицинских наук. 2020; 75 (4): 278–282. DOI: 10.15690/vramn1384.

  2. Bian D.J.H., Sabri S., Abdulkarim B.S. Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic. Cancers (Basel). 2022; 14 (15): 3598. DOI: 10.3390/cancers14153598.

  3. Rolfo C., Meshulami N., Russo A., Krammer F., García-Sastre A., Mack P.C., Gomez J.E., Bhardwaj N., Benyounes A., Sirera R., Moore A., Rohs N., Henschke C.I., Yankelevitz D., King J., Shyr Y., Bunn P.A.Jr., Minna J.D., Hirsch F.R. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. J Thorac Oncol. 2022; 17 (2): 214–227. DOI: 10.1016/j.jtho.2021.11.001.

  4. Гуляев П.В., Реснянская С.В., Островская И.В. Выявление постковидного синдрома у пациентов, перенесших новую коронавирусную инфекцию. Современные проблемы здравоохранения и медицинской статистики. 2022; (S2): 107–128. DOI: 10.24412/2312-2935-2022-2-107-128.

  5. Погосова Н.В., Палеев Ф.Н., Аушева А.К., Кучиев Д.Т., Гаман С.А., Веселова Т.Н., Белькинд М.Б., Соколова О.Ю., Жетишева Р.А., Терновой С.К., Бойцов С.А. Последствия COVID-19 на отдаленном этапе после госпитализации. Рациональная фармакотерапия в кардиологии. 2022; 18 (2): 118–126. DOI: 10.20996/1819-6446-2022-04-03.

  6. Charfeddine S., Ibn Hadj Amor H., Jdidi J., Torjmen S., Kraiem S., Hammami R., Bahloul A., Kallel N., Moussa N., Touil I., Ghrab A., Elghoul J., Meddeb Z., Thabet Y., Kammoun S., Bouslama K., Milouchi S., Abdessalem S., Abid L. Long COVID-19 Syndrome: Is It Related to Microcirculation and Endothelial Dysfunction? Insights From TUN-EndCOV Study. Front Cardiovasc Med. 2021; 8: 745758. DOI: 10.3389/fcvm.2021.745758.

  7. Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S., Mehra M.R., Schuepbach R.A., Ruschitzka F., Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395 (10234): 1417–1418. DOI: 10.1016/S0140-6736(20)30937-5.

  8. Carpenter T.C., Schomberg S., Stenmark K.R. Endothelin-mediated increases in lung VEGF content promote vascular leak in young rats exposed to viral infection and hypoxia. Am J Physiol Lung Cell Mol Physiol. 2005; 289 (6): L1075– L1082. DOI: 10.1152/ajplung.00251.2005.

  9. Barton M., Yanagisawa M. Endothelin: 30 Years From Discovery to Therapy. Hypertension. 2019; 74 (6): 1232–1265. DOI: 10.1161/HYPERTENSIONAHA.119.12105.

  10. Masaki T. Historical review: Endothelin. Trends Pharmacol Sci. 2004; 25 (4): 219–224. DOI: 10.1016/j.tips.2004.02.008.

  11. Krishnarao K., Bruno K.A., Di Florio D.N., Edenfield B.H., Whelan E.R., Macomb L.P., McGuire M.M., Hill A.R., Ray J.C., Cornell L.F., Tan W., Geiger X.J., Salomon G.R., Douglas, E.J., Fairweather D., Yamani M.H. Upregulation of Endothelin-1 May Predict Chemotherapy-Induced Cardiotoxicity in Women with Breast Cancer. Journal of clinical medicine. 2022; 11 (12): 3547. DOI: https://doi.org/10.3390/jcm11123547

  12. Tamkus D., Sikorskii A., Gallo K.A., Wiese D.A., Leece C., Madhukar B.V., Chivu S.C., Chitneni S., Dimitrov N.V. Endothelin-1 enriched tumor phenotype predicts breast cancer recurrence. ISRN Oncol. 2013; 2013: 385398. DOI: 10.1155/2013/385398.

  13. Gupta S., Prajapati A., Gulati M., Gautam S.K., Kumar S., Dalal V., Talmon G.A., Rachagani S., Jain M. Irreversible and sustained upregulation of endothelin axis during oncogene-associated pancreatic inflammation and cancer. Neoplasia. 2020; 22 (2): 98–110. DOI: 10.1016/j.neo.2019.11.001.

  14. Tocci P., Blandino G., Bagnato A. YAP and endothelin-1 signaling: an emerging alliance in cancer. J Exp Clin Cancer Res. 2021; 40: 27. DOI: https://doi.org/10.1186/s13046-021-01827-8

  15. Ahn H.M., Kim D.G., Kim Y.J. Blockade of endothelin receptor A enhances the therapeutic efficacy of gemcitabine in pancreatic cancer cells. Biochem Biophys Res Commun. 2020; 527 (2): 568–573. DOI: 10.1016/j.bbrc.2020.04.118.

  16. Bermejo-Martin J.F., Almansa R., Torres A., González-Rivera M., Kelvin D.J. COVID-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction. Cardiovasc Res. 2020; 116 (10): e132–e133. DOI: 10.1093/cvr/cvaa140.

  17. Abraham G.R., Kuc R.E., Althage M., Greasley P.J., Ambery P., Maguire J.J., Wilkinson I.B., Xu S.W., Ilyas I., Weng J.P. Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol Sin. 2022: 1–15. DOI: 10.1038/s41401-022-00998-0.

  18. Hoole S.P., Cheriyan J., Davenport A.P. Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19. J Mol Cell Cardiol. 2022; 167: 92–96. DOI: 10.1016/j.yjmcc.2022.03.007.

  19. Kadiyska T., Tourtourikov I., Dabchev K., Cherneva R., Stoynev N., Hadjiolova R., Mitev V., Spandidos D.A., Adamaki M., Zoumpourlis V. Role of endothelial dysfunction in the severity of COVID‑19 infection (Review). Mol Med Rep. 2022; 26 (5): 351. DOI: 10.3892/mmr.2022.12867.

  20. Santoro L., Falsetti L., Zaccone V., Nesci A., Tosato M., Giupponi B., Savastano M.C., Moroncini G., Gasbarrini A., Landi F., Santoliquido A. On Behalf Of Gemelli Against Covid-Post-Acute Care Study Group. Impaired Endothelial Function in Convalescent Phase of COVID-19: A 3 Month Follow Up Observational Prospective Study. J Clin Med. 2022; 11 (7): 1774. DOI: 10.3390/jcm11071774.

  21. Oikonomou E., Souvaliotis N., Lampsas S., Siasos G., Poulakou G., Theofilis P., Papaioannou T.G., Haidich A.B., Tsaousi G., Ntousopoulos V., Sakka V., Charalambous G., Rapti V., Raftopoulou S., Syrigos K., Tsioufis C., Tousoulis D., Vavuranakis M. Endothelial dysfunction in acute and long standing COVID-19: A prospective cohort study. Vascul Pharmacol. 2022; 144: 106975. DOI: 10.1016/j.vph.2022.106975.

  22. Haffke M., Freitag H., Rudolf G., Seifert M., Doehner W., Scherbakov N., Hanitsch L., Wittke K., Bauer S., Konietschke F., Paul F., Bellmann-Strobl J., Kedor C., Scheibenbogen C., Sotzny F. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). J Transl Med. 2022; 20: 138. DOI: https://doi.org/10.1186/s12967-022-03346-2

  23. Kedor C., Freitag H., Meyer-Arndt L., Wittke K., Hanitsch L.G., Zoller T., Steinbeis F., Haffke M., Rudolf G., Heidecker B., Bobbert T., Spranger J., Volk H.D., Skurk C., Konietschke F., Paul F., Behrends U., Bellmann-Strobl J., Scheibenbogen C. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. Nat Commun. 2022; 13 (1): 6009. DOI: 10.1038/s41467-022-33784-x.

  24. Петрищев Н.Н., Халепо О.В., Вавиленкова Ю.А., Власов Т.Д. COVID-19 и сосудистые нарушения (обзор литературы). Регионарное кровообращение и микроциркуляция. 2020; 19 (3): 90–98. DOI: 10.24884/1682-6655-2020-19-3-90-98.

  25. Золотницкая В.П., Амосов В.И., Титова О.Н., Агафонов А.О., Амосова О.В. Нарушения микроциркуляции в легких по данным перфузионной ОФЭКТ у пациентов в постковидном периоде. Российский электронный журнал лучевой диагностики. 2021; 11 (2): 8–18. DOI: 10.21569/2222-7415-2021-11-1-125-136.

  26. Sommer N., Schmeck B. Pulmonale Manifestationen bei Long-COVID [Pulmonary manifestations in long COVID]. Inn Med (Heidelb). 2022; 63 (8): 819–829. DOI: 10.1007/s00108-022-01371-3.

  27. Arun C., DeCatris M., Hemingway D.M., London N.J., O'Byrne K.J. Endothelin-1 is a novel prognostic factor in non-small cell lung cancer. Int J Biol Markers. 2004; 19 (4): 262–167. DOI: 10.1177/ 172460080401900402.

  28. Boldrini L., Gisfredi S., Ursino S., Faviana P., Lucchi M., Melfi F., Mussi A., Basolo F., Fontanini G. Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. Eur J Cancer. 2005; 41 (18): 2828–35. DOI: 10.1016/j.ejca.2005.08.030.

  29. Jiang Y., Liu Y., Shi Z., Wang B., Shang L., Xu X., Zhang S., Wang M. Expression and clinical relevance of uPA and ET-1 in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2011; 14 (1): 49–53. DOI: 10.3779/j.issn.1009-3419.2011.01.10.

  30. Rosanò L., Spinella F., Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2013; 13 (9): 637–651. DOI: 10.1038/nrc3546.

  31. Davenport A.P., Hyndman K.A., Dhaun N., Southan C., Kohan D.E., Pollock J.S., Pollock D.M., Webb D.J., Maguire J.J. Endothelin. Pharmacol Rev. 2016; 68 (2): 357–418. DOI: 10.1124/pr.115.011833.

  32. Rosanò L., Bagnato A. Endothelin therapeutics in cancer: Where are we? Am J Physiol Regul Integr Comp Physiol. 2016; 310 (6): R469–R475. DOI: 10.1152/ajpregu.00532.2015.

  33. Zhang Z., Chen L., Xu W., Sigdel K., Jiang X. Effects of silencing endothelin‑1 on invasion and vascular formation in lung cancer. Oncology Letters. 2017; 13: 4390–4396. DOI: https://doi.org/10.3892/ ol.2017.6027.

  34. Харагезов Д.А., Лазутин Ю.Н., Мирзоян Э.А., Милакин А.Г., Статешный О.Н., Лейман И.А., Чубарян А.В., Иозефи К.Д. Молекулярные мишени немелкоклеточного рака легкого (НМРЛ) вне «главной тройки». Южно-Российский онкологический журнал. 2021; 2 (4): 38–47. DOI: https://doi.org/10.37748/2686-9039-2021-2-4-5

  35. Moody T.W., Ramos-Alvarez I., Moreno P., Mantey S.A., Ridnour L., Wink D., Jensen R.T. Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells. Peptides. 2017; 90: 90–99. DOI: 10.1016/j.peptides.2017.01.012.

  36. Pulido I., Ollosi S., Aparisi S., Becker J.H., Aliena-Valero A., Benet M., Rodríguez M.L., López A., Tamayo-Torres E., Chuliá-Peris L., García-Cañaveras J.C., Soucheray M., Dalheim A.V., Salom J.B., Qiu W., Kaja S., Fernández-Coronado J.A., Alandes S., Alcácer J., Al-Shahrour F., Borgia J.A., Juan O., Nishimura M.I., Lahoz A., Carretero J., Shimamura T. Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma. Cancer Res. 2020; 80 (19): 4224–4232. DOI: 10.1158/0008-5472.CAN-20-0141.

  37. Spinella F., Caprara V., Cianfrocca R., Rosanò L., Di Castro V., Garrafa E., Natali P.G., Bagnato A. The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. Carcinogenesis. 2014; 35 (4): 840–848. DOI: 10.1093/carcin/bgu018.

  38. Weigert A., Zheng X., Nenzel A., Turkowski K., Günther S., Strack E., Sirait-Fischer E., Elwakeel E., Kur I.M., Nikam V.S., Valasarajan C., Winter H., Wissgott A., Voswinkel R., Grimminger F., Brüne B., Seeger W., Pullamsetti S.S., Savai R. Fibrocytes boost tumor-supportive phenotypic switches in the lung cancer niche via the endothelin system. Nat Commun. 2022; 13 (1): 6078. DOI: 10.1038/s41467-022-33458-8.

  39. Tostes R.C., Fortes Z.B., Callera G.E., Montezano A.C., Touyz R.M., Webb R.C., Carvalho M.H. Endothelin, sex and hypertension. Clin Sci (Lond). 2008; 114 (2): 85–97. DOI: 10.1042/CS20070169.

  40. Miller V.M., Mulvagh S.L. Sex steroids and endothelial function: translating basic science to clinical practice. Trends Pharmacol Sci. 2007; 28 (6): 263–270. DOI: 10.1016/j.tips.2007.04.004.

  41. Polderman K.H., Stehouwer C.D., van Kamp G.J., Schalkwijk C.G., Gooren L.J. Modulation of plasma endothelin levels by the menstrual cycle. Metabolism. 2000; 49 (5): 648–650. DOI: 10.1016/s0026-0495(00)80042-6.

  42. Wilbert-Lampen U., Seliger C., Trapp A., Straube F., Plasse A. Female sex hormones decrease constitutive endothelin-1 release via endothelial sigma-1/cocaine receptors: an action independent of the steroid hormone receptors. Endothelium. 2005; 12 (4): 185–191. DOI: 10.1080/10623320500227275.

  43. Чхаидзе И.З., Лиознов Д.А., Петрищев Н.Н., Ниаури Д.А. Системный эндотелиит при новой коронавирусной инфекции COVID-19: гендерные и перинатальные риски. Регионарное кровообращение и микроциркуляция. 2021; 20 (4): 4–13. DOI: 10.24884/1682-6655-2021-20-4-4-13.

  44. Ambrosino P., Calcaterra I., Molino A., Moretta P., Lupoli R., Spedicato G.A., Papa A., Motta A., Maniscalco M., Di Minno M.N.D. Persistent Endothelial Dysfunction in Post-Acute COVID-19 Syndrome:A Case-Control Study. Biomedicines. 2021; 9 (8): 957. DOI: 10.3390/biomedicines9080957.

 Поступила в редакцию 21.11.2022; принята 03.12.2022.

 

Авторский коллектив

Кит Олег Иванович – доктор медицинских наук, профессор, академик РАМН, генеральный директор, ФГБУ «НМИЦ онкологии» Минздрава России. 344037, Россия, г. Ростов-на-Дону, 14-я линия, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0003-3061-6108

Франциянц Елена Михайловна – доктор биологических наук, профессор, заместитель генерального директора, ФГБУ «НМИЦ онкологии» Минздрава России. 344037, Россия, г. Ростов-на-Дону, 14-я линия, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: http://orcid.org/0000-0003-3618-6890

Харагезов Дмитрий Акимович – кандидат медицинских наук, заведующий отделением торакальной хирургии, ФГБУ «НМИЦ онкологии» Минздрава России. 344037, Россия, г. Ростов-на-Дону, 14-я линия, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: http://orcid.org/0000-0003-0640-2994

Сурикова Екатерина Игоревна – кандидат биологических наук, старший научный сотрудник лаборатории изучения патогенеза злокачественных опухолей, ФГБУ «НМИЦ онкологии» Минздрава России. 344037, Россия, г. Ростов-на-Дону, 14-я линия, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0002-4318-7587

Горошинская Ирина Александровна – доктор биологических наук, профессор, старший научный сотрудник лаборатории изучения патогенеза злокачественных опухолей, ФГБУ «НМИЦ онкологии» Минздрава России. 344037, Россия, г. Ростов-на-Дону, 14-я линия, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0001-6265-8500

Бандовкина Валерия Ахтямовна – доктор биологических наук, старший научный сотрудник лаборатории изучения патогенеза злокачественных опухолей, ФГБУ «НМИЦ онкологии» Минздрава России. 344037, Россия, г. Ростов-на-Дону, 14-я линия, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: http://orcid.org/0000-0002-2302-8271

Черярина Наталья Дмитриевна – врач-лаборант лаборатории изучения патогенеза злокачественных опухолей, ФГБУ «НМИЦ онкологии» Минздрава России. 344037, Россия, г. Ростов-на-Дону, 14-я линия, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: http://orcid.org/0000-0002-3711-8155

Шихлярова Алла Ивановна, доктор биологических наук, профессор, старший научный сотрудник лаборатории изучения патогенеза злокачественных опухолей, ФГБУ «НМИЦ онкологии» Минздрава России. 344037, Россия, г. Ростов-на-Дону, 14-я линия, 63; e-mail This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0003-2943-7655

Погорелова Юлия Александровна – кандидат биологических наук, старший научный сотрудник лаборатории изучения патогенеза злокачественных опухолей, ФГБУ «НМИЦ онкологии» Минздрава России. 344037, Россия, г. Ростов-на-Дону, 14-я линия, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: http://orcid.org/0000-0002-2674-9832

Айрапетова Тамара Георгиевна – кандидат медицинских наук, хирург отделения торакальной хирургии, ФГБУ «НМИЦ онкологии» Минздрава России. 344037, Россия, г. Ростов-на-Дону, 14-я линия, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: https://orcid.org/0000-0003-4188-3746

Лазутин Юрий Николаевич – кандидат медицинских наук, доцент, ведущий научный сотрудник отдела торакальной хирургии, ФГБУ «НМИЦ онкологии» Минздрава России. 344037, Россия, г. Ростов-на-Дону, 14-я линия, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: http://orcid.org/0000-0002-6655-7632

Милакин Антон Григорьевич – онколог отделения торакальной хирургии, ФГБУ «НМИЦ онкологии» Минздрава России. 344037, Россия, г. Ростов-на-Дону, 14-я линия, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: http://orcid.org/0000-0002-2589-7606

Лейман Игорь Александрович – кандидат медицинских наук, врач-онколог отделения торакальной хирургии, ФГБУ «НМИЦ онкологии» Минздрава России. 344037, Россия, г. Ростов-на-Дону, 14-я линия, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: http://orcid.org/0000-0003-2572-1624

Статешный Олег Николаевич – онколог отделения торакальной хирургии, ФГБУ «НМИЦ онкологии» Минздрава России. 344037, Россия, г. Ростов-на-Дону, 14-я линия, 63; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., ORCID ID: http://orcid.org/0000-0003-4513-7548

 

Образец цитирования

Кит О.И., Франциянц Е.М., Харагезов Д.А., Сурикова Е.И., Горошинская И.А., Бандовкина В.А., Черярина Н.Д., Шихлярова А.И., Погорелова Ю.А., Айрапетова Т.Г., Лазутин Ю.Н., Милакин А.Г., Лейман И.А., Статешный О.Н. Уровень эндотелина-1 в крови и ткани легкого у больных немелкоклеточным раком легкого, перенесших COVID-19 различной степени тяжести. Ульяновский медико-биологический журнал. 2023; 1: 74–90. DOI: 10.34014/2227-1848-2023-1-74-90